Technical Notes Covering Biotech Stocks -- Aeterna Zentaris, Oncolytics Biotech, Alexion Pharma, Synergy Pharma, and MEI Pharma

May 15, 2015, 09:00 ET from Investor-Edge

LONDON, May 15, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Aeterna Zentaris Inc. (NASDAQ: AEZS), Oncolytics Biotech Inc. (NASDAQ: ONCY), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), and MEI Pharma Inc. (NASDAQ: MEIP). Free research report on Aeterna Zentaris can be accessed at http://get.Investor-Edge.com/pdf/?c=Aeterna%20Zentaris&d=15-May-2015&s=AEZS. The US markets on Thursday, May 14, 2015, ended on a positive note as the Dow Jones Industrial Average finished at 18,252.24, up 1.06% and the NASDAQ Composite closed at 5,050.80, up 1.39%. The S&P 500 finished the session 1.08% higher at 2,121.10. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 855.74, up 1.41%, with the index advancing 4.64% in the previous three months. Register for your complimentary reports at the links given below.  

Aeterna Zentaris Inc.'s stock edged 0.20% higher, to close the day at $0.44. The stock recorded a trading volume of 1.25 million shares, below its three months average volume of 2.63 million shares. The company's shares oscillated between $0.43 and $0.45 during the session. Over the last three trading sessions and over the past one month, Aeterna Zentaris Inc.'s shares have declined 6.09% and 24.25%, respectively. Furthermore, the stock has lost 17.47% in the previous three months. The company is trading below its 50-day and 200-day moving averages. Aeterna Zentaris Inc.'s 200-day moving average of $0.82 is above its 50-day moving average of $0.56. Additionally, the stock has a Relative Strength Index (RSI) of 31.23. Sign up and read the free notes on AEZS at:

http://get.Investor-Edge.com/pdf/?c=Aeterna%20Zentaris&d=15-May-2015&s=AEZS

On Thursday, shares in Oncolytics Biotech Inc. recorded a trading volume of 0.47 million shares, lower than its three months average volume of 2.47 million shares. The stock ended the day at $0.71, which was 1.72% below its previous day's closing of $0.73, and registered an intraday range of $0.71 and $0.75. Oncolytics Biotech Inc.'s shares have surged 9.85% in the last one month, 39.15% in the previous three months, and 34.72% on YTD basis. The company is trading below its 50-day and 200-day moving averages of $0.77 and $0.76, respectively. Furthermore, shares of Oncolytics Biotech Inc. have an RSI of 47.94. The complimentary notes on ONCY can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Oncolytics%20Biotech&d=15-May-2015&s=ONCY

Alexion Pharmaceuticals Inc.'s stock gained 1.43% to end Thursday's session at $161.69. The stock recorded a trading volume of 1.87 million shares, above its three months average volume of 1.64 million shares. The company's shares fluctuated between $156.54 and $161.96 during the session. Shares of the company traded at a PE ratio of 51.79. Alexion Pharmaceuticals Inc.'s shares have advanced 0.40% in the previous three trading sessions. However, the stock has lost 11.51% over the last one month and 11.30% over the past three months. The company is trading below its 50-day and 200-day moving averages. Alexion Pharmaceuticals Inc.'s 200-day moving average of $177.68 is above its 50-day moving average of $177.21. Additionally, the stock has an RSI of 35.34. Register for free on Investor-Edge and access the latest research on ALXN at:

http://get.Investor-Edge.com/pdf/?c=Alexion%20Pharma&d=15-May-2015&s=ALXN

On Thursday, shares in Synergy Pharmaceuticals Inc. fluctuated between $3.35 and $3.53 before ending the session 1.75% higher at $3.48. The stock reported a trading volume of 1.36 million shares, lower than its three months average volume of 1.78 million shares. Although Synergy Pharmaceuticals Inc.'s stock has fallen by 3.60% in the previous three trading sessions, it has gained 16.58% in the last three months and 14.10% on YTD basis. The company is trading above its 200-day moving average of $3.33, which is below the 50-day moving average of $3.90. Moreover, shares of Synergy Pharmaceuticals Inc. have an RSI of 37.13. The complete research on SGYP is available for free at:

http://get.Investor-Edge.com/pdf/?c=Synergy%20Pharma&d=15-May-2015&s=SGYP

MEI Pharma Inc.'s stock finished Thursday's session 2.53% higher at $2.03. A total of 0.91 million shares were traded, which was below its three months average volume of 2.04 million shares. The stock vacillated between $1.87 and $2.03 during the session. The stock has gained 5.18% in the last one month. However, over the past three months and since the beginning of 2015, MEI Pharma Inc.'s shares have declined 59.40% and 52.46%, respectively. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $5.32 is greater than its 50-day moving average of $3.00. MEI Pharma Inc.'s stock has an RSI of 36.70. Free in depth research on MEIP is available at:

http://get.Investor-Edge.com/pdf/?c=MEI%20Pharma&d=15-May-2015&s=MEIP

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge